(KYMR) Kymera Therapeutics - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US5015751044
Stock: IRAK4, STAT6, TYK2, Protein Degradation
Total Rating 40
Risk 36
Buy Signal 0.47
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 66.7% |
| Relative Tail Risk | -11.5% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.16 |
| Alpha | 73.93 |
| Character TTM | |
|---|---|
| Beta | 1.440 |
| Beta Downside | 1.291 |
| Drawdowns 3y | |
|---|---|
| Max DD | 70.69% |
| CAGR/Max DD | 0.39 |
Description: KYMR Kymera Therapeutics January 11, 2026
Kymera Therapeutics (NASDAQ: KYMR) is a clinical-stage biotech that builds small-molecule degraders to eliminate disease-causing proteins via the body’s ubiquitin-proteasome system. Its lead pipeline includes a Phase II IRAK4 inhibitor for hidradenitis suppurativa and atopic dermatitis, a STAT6 program targeting type-2 inflammation, and a TYK2 candidate for broader autoimmune indications. Kymera also holds a strategic alliance with Sanofi to co-develop IRAK4 therapeutics outside oncology.
As of the latest filing, Kymera reported a cash runway extending through Q4 2025 and raised roughly $150 million in a 2023 private placement, bolstering its R&D budget. The protein-degradation market is projected to grow at a ~12 % CAGR through 2030, providing a macro-level tailwind for the company’s modality. Within the broader biotechnology sector, peer-group revenue multiples have compressed by ~8 % year-over-year, reflecting heightened scrutiny on cash-burn and milestone-driven pipelines.
For a deeper dive into KYMR’s valuation metrics and peer comparison, you might explore the ValueRay platform.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: -295.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.21 > 0.02 and ΔFCF/TA -6.57 > 1.0 |
| NWC/Revenue: 1044 % < 20% (prev 573.5%; Δ 470.8% < -1%) |
| CFO/TA -0.21 > 3% & CFO -227.9m > Net Income -295.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 7.38 > 1.5 & < 3 |
| Outstanding Shares: last quarter (87.3m) vs 12m ago 14.68% < -2% |
| Gross Margin: -83.38% > 18% (prev 0.93%; Δ -8431 % > 0.5%) |
| Asset Turnover: 4.09% > 50% (prev 8.46%; Δ -4.37% > 0%) |
| Interest Coverage Ratio: -875.0 > 6 (EBITDA TTM -285.9m / Interest Expense TTM 337.0k) |
Altman Z'' -8.62
| A: 0.41 (Total Current Assets 528.3m - Total Current Liabilities 71.6m) / Total Assets 1.10b |
| B: -0.89 (Retained Earnings -979.0m / Total Assets 1.10b) |
| C: -0.28 (EBIT TTM -294.9m / Avg Total Assets 1.07b) |
| D: -6.27 (Book Value of Equity -977.5m / Total Liabilities 155.8m) |
| Altman-Z'' Score: -8.62 = D |
Beneish M -2.94
| DSRI: 1.44 (Receivables 947.0k/1.32m, Revenue 43.7m/87.6m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 1.24 (AQ_t 0.44 / AQ_t-1 0.35) |
| SGI: 0.50 (Revenue 43.7m / 87.6m) |
| TATA: -0.06 (NI -295.1m - CFO -227.9m) / TA 1.10b) |
| Beneish M-Score: -2.94 (Cap -4..+1) = A |
What is the price of KYMR shares?
As of February 04, 2026, the stock is trading at USD 77.22 with a total of 648,355 shares traded.
Over the past week, the price has changed by +7.03%, over one month by +6.64%, over three months by +29.30% and over the past year by +100.62%.
Over the past week, the price has changed by +7.03%, over one month by +6.64%, over three months by +29.30% and over the past year by +100.62%.
Is KYMR a buy, sell or hold?
Kymera Therapeutics has received a consensus analysts rating of 4.55.
Therefore, it is recommended to buy KYMR.
- StrongBuy: 14
- Buy: 3
- Hold: 3
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the KYMR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 116.7 | 51.1% |
| Analysts Target Price | 116.7 | 51.1% |
| ValueRay Target Price | 85.1 | 10.2% |
KYMR Fundamental Data Overview January 31, 2026
P/S = 135.1944
P/B = 6.0173
Revenue TTM = 43.7m USD
EBIT TTM = -294.9m USD
EBITDA TTM = -285.9m USD
Long Term Debt = 84.0m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 13.7m USD (from shortTermDebt, last quarter)
Debt = 84.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -29.0m USD (from netDebt column, last quarter)
Enterprise Value = 5.49b USD (5.91b + Debt 84.0m - CCE 505.7m)
Interest Coverage Ratio = -875.0 (Ebit TTM -294.9m / Interest Expense TTM 337.0k)
EV/FCF = -23.85x (Enterprise Value 5.49b / FCF TTM -230.2m)
FCF Yield = -4.19% (FCF TTM -230.2m / Enterprise Value 5.49b)
FCF Margin = -526.4% (FCF TTM -230.2m / Revenue TTM 43.7m)
Net Margin = -674.8% (Net Income TTM -295.1m / Revenue TTM 43.7m)
Gross Margin = -83.38% ((Revenue TTM 43.7m - Cost of Revenue TTM 80.2m) / Revenue TTM)
Gross Margin QoQ = none% (prev 81.84%)
Tobins Q-Ratio = 4.98 (Enterprise Value 5.49b / Total Assets 1.10b)
Interest Expense / Debt = 0.12% (Interest Expense 98.0k / Debt 84.0m)
Taxrate = 21.0% (US default 21%)
NOPAT = -233.0m (EBIT -294.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.38 (Total Current Assets 528.3m / Total Current Liabilities 71.6m)
Debt / Equity = 0.09 (Debt 84.0m / totalStockholderEquity, last quarter 946.3m)
Debt / EBITDA = 0.10 (negative EBITDA) (Net Debt -29.0m / EBITDA -285.9m)
Debt / FCF = 0.13 (negative FCF - burning cash) (Net Debt -29.0m / FCF TTM -230.2m)
Total Stockholder Equity = 884.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -27.62% (Net Income -295.1m / Total Assets 1.10b)
RoE = -33.35% (Net Income TTM -295.1m / Total Stockholder Equity 884.9m)
RoCE = -30.43% (EBIT -294.9m / Capital Employed (Equity 884.9m + L.T.Debt 84.0m))
RoIC = -26.33% (negative operating profit) (NOPAT -233.0m / Invested Capital 884.9m)
WACC = 11.06% (E(5.91b)/V(6.00b) * Re(11.22%) + D(84.0m)/V(6.00b) * Rd(0.12%) * (1-Tc(0.21)))
Discount Rate = 11.22% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 22.14%
Fair Price DCF = unknown (Cash Flow -230.2m)
EPS Correlation: 13.08 | EPS CAGR: 37.02% | SUE: 4.0 | # QB: 1
Revenue Correlation: -31.53 | Revenue CAGR: -36.61% | SUE: -1.95 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.90 | Chg30d=+0.069 | Revisions Net=+3 | Analysts=11
EPS next Year (2026-12-31): EPS=-3.73 | Chg30d=-0.024 | Revisions Net=+8 | Growth EPS=-7.0% | Growth Revenue=-11.2%
P/B = 6.0173
Revenue TTM = 43.7m USD
EBIT TTM = -294.9m USD
EBITDA TTM = -285.9m USD
Long Term Debt = 84.0m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 13.7m USD (from shortTermDebt, last quarter)
Debt = 84.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -29.0m USD (from netDebt column, last quarter)
Enterprise Value = 5.49b USD (5.91b + Debt 84.0m - CCE 505.7m)
Interest Coverage Ratio = -875.0 (Ebit TTM -294.9m / Interest Expense TTM 337.0k)
EV/FCF = -23.85x (Enterprise Value 5.49b / FCF TTM -230.2m)
FCF Yield = -4.19% (FCF TTM -230.2m / Enterprise Value 5.49b)
FCF Margin = -526.4% (FCF TTM -230.2m / Revenue TTM 43.7m)
Net Margin = -674.8% (Net Income TTM -295.1m / Revenue TTM 43.7m)
Gross Margin = -83.38% ((Revenue TTM 43.7m - Cost of Revenue TTM 80.2m) / Revenue TTM)
Gross Margin QoQ = none% (prev 81.84%)
Tobins Q-Ratio = 4.98 (Enterprise Value 5.49b / Total Assets 1.10b)
Interest Expense / Debt = 0.12% (Interest Expense 98.0k / Debt 84.0m)
Taxrate = 21.0% (US default 21%)
NOPAT = -233.0m (EBIT -294.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.38 (Total Current Assets 528.3m / Total Current Liabilities 71.6m)
Debt / Equity = 0.09 (Debt 84.0m / totalStockholderEquity, last quarter 946.3m)
Debt / EBITDA = 0.10 (negative EBITDA) (Net Debt -29.0m / EBITDA -285.9m)
Debt / FCF = 0.13 (negative FCF - burning cash) (Net Debt -29.0m / FCF TTM -230.2m)
Total Stockholder Equity = 884.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -27.62% (Net Income -295.1m / Total Assets 1.10b)
RoE = -33.35% (Net Income TTM -295.1m / Total Stockholder Equity 884.9m)
RoCE = -30.43% (EBIT -294.9m / Capital Employed (Equity 884.9m + L.T.Debt 84.0m))
RoIC = -26.33% (negative operating profit) (NOPAT -233.0m / Invested Capital 884.9m)
WACC = 11.06% (E(5.91b)/V(6.00b) * Re(11.22%) + D(84.0m)/V(6.00b) * Rd(0.12%) * (1-Tc(0.21)))
Discount Rate = 11.22% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 22.14%
Fair Price DCF = unknown (Cash Flow -230.2m)
EPS Correlation: 13.08 | EPS CAGR: 37.02% | SUE: 4.0 | # QB: 1
Revenue Correlation: -31.53 | Revenue CAGR: -36.61% | SUE: -1.95 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.90 | Chg30d=+0.069 | Revisions Net=+3 | Analysts=11
EPS next Year (2026-12-31): EPS=-3.73 | Chg30d=-0.024 | Revisions Net=+8 | Growth EPS=-7.0% | Growth Revenue=-11.2%